Form 8-K - Current report:
SEC Accession No. 0001104659-22-126475
Filing Date
2022-12-13
Accepted
2022-12-13 08:38:35
Documents
13
Period of Report
2022-12-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2232491d1_8k.htm   iXBRL 8-K 27560
2 EXHIBIT 99.1 tm2232491d1_ex99-1.htm EX-99.1 16124
  Complete submission text file 0001104659-22-126475.txt   222917

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sls-20221213.xsd EX-101.SCH 3060
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sls-20221213_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sls-20221213_pre.xml EX-101.PRE 22614
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2232491d1_8k_htm.xml XML 3610
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 221458603
SIC: 2834 Pharmaceutical Preparations